Obesity cardiomyopathy: pathogenesis and pathophysiology.
Obesity is becoming a worldwide phenomenon. Myocardial changes associated with the obese state are increasingly recognized, independent of hypertension, obstructive sleep apnea and coronary artery disease. The existence of a cardiomyopathy of obesity is supported by a range of evidence: epidemiologic study findings, which have shown an association between obesity and heart failure; clinical studies that have confirmed the association of adiposity with left ventricular dysfunction, independent of hypertension, coronary artery disease and other heart disease; and experimental evidence of structural and functional changes in the myocardium in response to increased adiposity. The most important mechanisms in the development of obesity cardiomyopathy are metabolic disturbances (insulin resistance, increased free fatty acid levels, and also increased levels of adipokines), activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, myocardial remodeling, and small-vessel disease (both microangiopathy and endothelial dysfunction). In the first part of this two-part Review, we seek to evaluate the emerging evidence for the existence of a cardiomyopathy of obesity and clarify the responsible mechanisms.
Wong
Chiew
C
Alfred Hospital and the Baker Heart Research Institute, Melbourne, Australia.
Marwick
Thomas H
TH
D009202:Cardiomyopathies / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D015897:Comorbidity; D006801:Humans; D050356:Lipid Metabolism; D009765:Obesity / Q000150:complications* / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D012307:Risk Factors